MedTrace Logo

To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

NCT05737771 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-21

No results posted yet for this study

Summary

To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.

Conditions

  • FDC
  • Diabetes Mellitus, Type 2

Interventions

DRUG

DWC202213

DWC202213

DRUG

DWJ1563

DWJ1563

DRUG

DWP16001

DWP16001

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2023-03-31
Completion
2023-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737771 on ClinicalTrials.gov